ARS Pharmaceuticals
SPRY
SPRY
89 hedge funds and large institutions have $348M invested in ARS Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 33 increasing their positions, 17 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
18% less capital invested
Capital invested by funds: $425M → $348M (-$77.3M)
82.52% less ownership
Funds ownership: 139.11% → 56.59% (-83%)
Holders
89
Holding in Top 10
3
Calls
$5.9M
Puts
$1.01M
Top Buyers
| 1 | +$6.53M | |
| 2 | +$4.92M | |
| 3 | +$3.19M | |
| 4 |
RA
Royce & Associates
New York
|
+$1.98M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.74M |
Top Sellers
| 1 | -$4.31M | |
| 2 | -$2.71M | |
| 3 | -$1.83M | |
| 4 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$1.56M |
| 5 |
NYLIM
New York Life Investment Management
New York
|
-$1.38M |